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Abstract
Objectives To measure the effects on symptoms of electri-
cal cardioversion (DC) in patients with atrial fibrillation
(AF) by means of a new, short, validated, AF-specific
questionnaire, the AF6.
Methods One hundred eleven patients (67±12 years, 89
men) were screened before and 12±3 days after DC using
AF6, covering ‘breathing difficulties at rest’, ‘breathing
difficulties on exertion’, ‘limitations in day-to-day life due
to atrial fibrillation’, ‘feeling of discomfort due to atrial
fibrillation’, ‘tiredness due to atrial fibrillation’, and ‘worry/
anxiety due to atrial fibrillation’. A single global score was
calculated. The Toronto AF Symptoms and Severity Check
List (AFSS) and the generic SF-36 were also administered.
Patients in sinus rhythm at 12±3 days (n=56) were defined
as responders and patients in AF (n=55) as non-responders.
Results The mean single global score decreased in all
patients (18±12.4 to 13±11.6, p<0.0001) and in responders
(22±14vs.12±12,p<0.01) but not in non-responders (14±9
vs. 14±11, N.S). The AFSS frequency scores decreased from
14.5±7.7 to 9.5±7.8 in responders, p=0.001, but not in non-
responders. There was a strong correlation between changes
in the AF6 and the SF-36 regarding four of the six items.
Effect sizes of AF6 ranged from 0 to 0.52 in all patients, in
responders from 0.10 to 0.85 and in non-responders from
−0.23 to 0.34, the highest figures consistently referring to
‘tiredness due to atrial fibrillation’.
Conclusions The symptom scores measured by AF6 de-
creased significantly, especially in responders. AF6 demon-
strated adequate responsiveness to change, and effect sizes
were mostly moderate, in responders moderate to high.
Keywords Atrial fibrillation.AF6.Responsiveness.
Symptoms.AF specific instrument
1 Introduction
Patients with atrial fibrillation (AF) can experience any-
thing from no to unbearable symptoms. The symptoms
often have an impact on their health-related quality of life
(HRQL) [1–3] and frequently cause patients to seek
medical help. As symptoms in AF are so diverse, it may
be difficult to estimate whether an individual patient would
benefit symptomatically from a treatment attempt, e.g.,
cardioversion [4, 5]. No single symptom is truly AF
specific, however, and almost any of the symptoms could
also be caused by a concomitant condition. Evaluating the
symptoms in a patient with AF may thus be a challenge,
and there is still an unmet need for tools that can capture
the patient-reported symptoms caused by AF.
At present, the generic Short Form 36 (SF-36) is the
most frequently used tool to assess HRQL and is also used
in patient populations with AF [6–10]. The AF disease-
specific Toronto AF Symptoms and Severity Check List
(AFSS) is frequently used to assess symptoms and covers
both the frequency and the severity of AF episodes [7, 8,
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validationofa new, disease-specific, veryshort questionnaire,
AF6, which was developed as an instrument to assess the
baselinesymptomburdenandtoberesponsivetochangesdue
to treatment [13]. The present report evaluates the ability of
the AF6 to detect change following elective direct current
electrical cardioversion (DC) in patients with persistent AF.
2 Patients and methods
Patients with persistent AF scheduled for DC were asked to
participate inthe study.There werenopre-specifiedexclusion
criteria other than inability to understand and respond to the
questions or unwillingness to participate. The patients were
familiar with the term atrial fibrillation, received information
about the instrument, and completed the instrument prior to
any clinical examination or intervention (the day before DC
and at their follow-up visit 12±3 days after DC). Neither the
study nurse nor the patient knew the actual rhythm until after
the questionnaire was completed. Patients were interviewed
abouttheirunderlyingheartdiseasesandotherco-morbidities,
and their medical and specific arrhythmia history. A 12-lead
electrocardiogram (ECG) and an echocardiography were
performed according to the clinical routine. The study was
part of the quality assurance program of the clinic. Elective
DC took place in a nurse-led outpatient clinic with physician
back-up. After 4 weeks with a therapeutic international
normalized ratio (INR), the patients were invited to the clinic
the day before DC for a 30-min information and preparation
visit with routine laboratory tests, a 12-lead ECG and blood
pressuremeasurements.TheDCwas performedthe following
day under a short general anesthesia with propofol, using
biphasic waveform shocks of 70-200J. After DC and 2-3 h of
observation, the patient met their cardiologist before dis-
charge. All patients returned to the AF nurse 12±3 days after
DCforarhythmcontrol.Patientswhowereconvertedtosinus
rhythm(SR) andhadSRatthe follow-upvisitweredefinedas
clinical responders, while those who were in AF at follow-up
were defined as clinical non-responders.
2.1 AF6
The six items of AF6 summarize the most frequent problems
named by patients in their contact with the nurse at the AF
clinic. They focus on: item 1 ‘breathing difficulties at rest’,i t e m
2 ‘breathing difficulties on exertion’, item 3 ‘limitations in day-
to-day life due to atrial fibrillation’,i t e m4‘feeling of
discomfort due to atrial fibrillation’, item 5 ‘tiredness due to
atrial fibrillation’ and item 6 ‘worry/anxiety due to atrial
fibrillation’. Patients choose a number on a Likert scale from 0
to 10, where 0 means no and 10 severe symptoms or
difficulties, and the scores of the six questions are added into
a single global score. The recall period for the instrument is the
most recent 7 days.
AF6 has undergone psychometric validation, showing
adequate internal consistency reliability with a Cronbach’s
α of 0.81. Test-retest reliability was done in patients who
failed DC and was >0.70 for three of the six items. The
patients also completed the SF-36 generic quality of life
instrument [6] and the AFSS [12]. Data gathered in the SF-
36 were used in the validation process of the AF6, and the
AFSS was chosen as a frequently used measure to provide
additional information, although it has not been validated in
its Swedish translation. The Pearson correlation coefficients
were used to assess the convergent and discriminant
validity, and items 1 and 2 correlated strongly or moder-
ately well with four of the eight SF-36 domains, item 5 with
five domains, item 7 with six and items 4 and 6 with all
eight domains. All items at baseline were compared against
three levels of symptom severity obtained from the AFSS.
“No”, “mild”, “moderate” and “severe” symptoms were
reflected in low to high scores showing known-groups
validity. Finally, the items were tested individually in the
Rasch analysis and represented one domain, their range of
locations being −0.43 to +0.41 [13].
3 Statistical methods
Values are expressed as mean ± standard deviations (SD) and
as median with interquartile ranges. Student’s t test was used
to test differences between responders and non-responders.
All p values are two-tailed and considered statistically
significant if below 0.05. Correlation coefficients of changes
in the items of the new instrument and changes in the SF-36
domains were determined, after adjustment for Bonferroni
multiplicity at a level of p<0.0001 statistical significance.
Effect sizes and standardized response mean values were
calculated overall and in responders (patients who achieved
and maintained SR) and non-responders (patients who did
not achieve SR or relapsed into AF after an initially
successful DC) using the following formula: mean score at
follow-up—mean score at baseline/standard deviation of
baseline scores [14]. The effect size was characterized as
small (>0.2 but <0.5), moderate (0.5-0.8) or large (>0.8)
according to guidelines proposed by Cohen [15].
4 Results
In total, 137 patients were identified and eligible, 11 of whom
did not wish to participate (for reasons of a lack of time and not
wishing to answer questions about their symptoms). One was
not included because of language problems. Fourteen patients
were excluded because of non-therapeutic INR values (n=3),
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(n=1) or for administrative reasons (n=9). Thus, the study
population consisted of 111 patients, 89 men and 22 women.
At DC, 102 (92%) patients converted to SR, 93 of whom
(84%) had SR at discharge and 56 (50%) who converted to
SR and remained in SR at 12±3 days. Nine patients did not
convert to SR at all, and nine patients relapsed within 2 h.
Patient baseline characteristics are shown in Table 1.T h e
mean duration of the ongoing AF episode was 5.8±
8.1 months. Most patients were on rhythm control agents at
the time of DC, and there was no change in medication in
most patients between the DC and the follow-up visit.
Responders at 12±3days
All Yes No
Number of patients 111 56 55
Men, n (%) 89 (80) 46 (82) 43 (78)
Age, years 67±12 66±11 67±13
Weight, kg 86±20 85±17 86±22
Length, cm 178±9 177±9 178±10
BMI 27±5 27±5 27±5
Episode duration of AF, months 5.8±8.1 4.8±5.4 6.9±10.1
First episode of AF (n)3 6 2 0 1 6
Hypothyreosis 2 (2) 1 (2) 1 (2)
Hyperthyreosis 2 (2) 2 (4) 0 (0)
Hypertension 45 (41) 26 (46) 19 (35)
Angina pectoris 18 (16) 10 (18) 8 (15)
Previous acute myocardial infarction 17 (15) 7 (13) 10 (18)
Previous CABG 12 (11) 7 (13) 5 (9)
Previous PCI 9 (8) 3 (5) 6 (11)
Diabetes mellitus 13 (12) 5 (9) 8 (15)
Heart failure 25 (23) 13 (23) 12 (22)
Dilated CMP 11 (10) 6 (11) 5 (9)
Hypertrophic CMP 3 (3) 3 (5) 0 (0)
Stroke 6 (5) 3 (5) 3 (5)
TIA 7 (6) 0 (0) 7 (13)
Venous trombosis 1 (1) 1 (2) 0 (0)
Peripheral arterial embolism 1 (1) 0 (0) 1 (2)
Pulmonary embolism 1 (1) 1 (2) 0 (0)
Table 1 Baseline characteristics
Mean±SD percent within
brackets, BMI body mass index,
CABG coronary artery bypass-
surgery, CMP cardiomyopathy,
PCI percutaneous coronary in-
tervention, TIA transient ische-
mic attack
Before DC 12±3days after DC Before DC 12±3days after DC
Nonresponders (n=55) Responders (n=56)
Waran 55 (100) 55 (100) 56 (100) 56 (100)
Digoxin 12 (22) 8 (15) 9 (16) 6 (11)
Amiodarone 5 (9) 5 (9) 6 (11) 6 (11)
Sotalol 15 (27) 13 (24) 12 (21) 15 (27)
β-blocker 26 (47) 31 (56) 35 (63) 32 (57)
Diuretics 22 (40) 21 (38) 13 (23) 16 (29)
Lipid-lowering drug 15 (27) 16 (29) 22 (39) 20 (36)
ARB 10 (18) 9 (16) 8 (14) 9 (16)
ACE-I 10 (18) 12 (22) 18 (32) 19 (34)
Calcium blocker 10 (18) 11 (20) 8 (14) 7 (13)
Potassium 4 (7) 5 (9) 1 (2) 2 (4)
Spironolactone 3 (5) 4 (7) 4 (7) 5 (9)
Sleep and Sedatives 9 (16) 8 (15) 6 (11) 6 (11)
Table 2 Medications were sta-
ble between visits before and
after DC cardioversion
Percent within brackets
ARB angiotensin II receptor an-
tagonist, ACE-I angiotensin-
converting enzyme inhibitor
J Interv Card Electrophysiol (2010) 28:185–191 1874.1 The AF symptom burden at baseline
The mean single global score (composite of items 1-6) at
baseline was 18±12.4. The items with the highest scores at
baseline were ‘tiredness due to atrial fibrillation’ (item 5),
4.5±3.2, and ‘breathing difficulties upon exertion’ (item 2),
4.5±3.2. The items with the lowest scores were ‘breathing
difficulties at rest’ (item 1), 1.0±1.6, and ‘worry/anxiety
due to atrial fibrillation’ (item 6), 2.1±2.9 (Table 2).
No patient scored 0 in all six items before or after DC. At
baseline, the most frequent symptoms were ‘tiredness due to
atrial fibrillation’ (item 5) and ‘breathing difficulties upon
exertion’ (item 2) and were found in 83% and 80% of the
patients, respectively. The least frequent symptoms at baseline,
‘breathing difficulties atrest’(item 1) and ‘worry/anxiety due to
atrial fibrillation’ (item 6) were found in 36% and 48% of the
patients, respectively. The other items, ‘limitations in day-to-
day life due to atrial fibrillation’ (item 3) and ‘feeling of
discomfort due to atrial fibrillation’ (item 4) were present in
65% and 64% of the patients, respectively. At baseline, the
mean single global score and the mean scores per item were
consistently higher in subsequent responders than in non-
responders, with the exception of ‘breathing difficulties at rest’
(item 1). The single global score and the mean per item score
decreased after conversion to SR in responders but did not
change in patients remaining in or relapsing to AF.
The means and SD of each item are shown in Table 3.
When the mean value of each item was calculated and
included only patients with a value of ≥1 on the Likert scale
(i.e., included only patients experiencing the symptom
posed in the question), the figures for each item were 2.1
(item 1), 5.4 (item 2), 5.1 (item 3), 3.9 (item 4), 5.7 (item 5)
and 5.7 (item 6). This analysis shows that ‘worry/anxiety
due to atrial fibrillation’ (item 6), when present, was an
important symptom, while ‘breathing difficulties at rest’
(item 1) was not.
4.2 Symptom reduction after DC cardioversion
The single global mean score decreased from 18±12.4 to
13±11.6, p<0.0001 in the total study population. There
were statistically significant decreases in four of the items
(Table 3). The single global mean score decreased in
responders from 22±14 to 12±12, p<0.01, but not in non-
responders, 14±9 and 14±11.
4.3 Responsiveness of AF6
The mean changes in individual AF6 item scores ranged
from −0.01 to 1.7 (statistically significant in four items, p<
0.005), while the mean changes in individual items in
responders were 0.2 to 2.8 (statistically significant in five
items p<0.005) versus none in non-responders. The effect
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188 J Interv Card Electrophysiol (2010) 28:185–191size (ES) ranged from 0 (‘breathing difficulties at rest’, item
1) to 0.52 (‘tiredness due to atrial fibrillation’, item 5), and
the SRM ranged from 0 (‘breathing difficulties at rest’, item
1) to 0.53 (‘tiredness due to atrial fibrillation’, item 5;
Table 4). ES in responders were between 0.10 (‘breathing
difficulties at rest’, item 1) and 0.85 (‘tiredness due to atrial
fibrillation’, item 5) with corresponding SRMs of 0.09 and
0.83, respectively (Table 4). ES in non-responders were
small and ranged between −0.23 and 0.34.
4.4 Toronto AF symptoms and severity check list
Atbaseline,allpatientsreportedsomesymptomsaccordingto
the AFSS. The most frequently reported symptoms were
tiredness,irregularheartrhythmanddyspneaonexertion.The
patients who reported symptoms “always” and “frequently”
werethosewithanotablereductionafterDC,whilethosewith
symptoms “sometimes”, “relatively rarely” or “never” were
largely unchanged. At baseline, responders had a higher
frequency score than non-responders, 14.5±7.7 versus 10.8±
7.3, and a higher severity score, 12.2±7.3 versus 8.6±5.8,
respectively. Most symptoms were mild to moderate. At the
12±3-day follow-up, the frequency score of the responders
had decreased from 14.5±7.7 to 9.5±7.8, p=0.0011, and the
severity score from 12.2±7.3 to 7.7±7.1, p=0.0013. There
was no change in frequency in non-responders, 10.8±7.3
versus 11.5±8.0, N.S., or in severity score, 8.6±5.8 versus
8.7±5.7, N.S.
4.5 SF-36
The correlation coefficients between changes in the AF6
instrument and changes in the SF-36 domains are shown in
Table 4. There was a strong correlation between the two
instruments regarding four of the six remaining items in the
AF6: between ‘breathing difficulties upon exertion’ (item
2) and physical functioning and vitality; between ‘limitation
in day-to-day life due to atrial fibrillation’ (item 3) and
physical functioning, role physical and vitality; between
‘feeling of discomfort due to atrial fibrillation’ (item 4) and
physical functioning and vitality; and between ‘tiredness
due to AF’ (item 5) and physical functioning, vitality and
role-emotional. There was no correlation between changes
in ‘breathing difficulties at rest’ (item 1) and ‘worry/anxiety
due to atrial fibrillation’ (item 6) and changes in any of the
domains of the SF-36.
5 Discussion
The AF6 showed adequate responsiveness to the changes in
symptoms caused by restoration and maintenance of SR
after successful DC cardioversion. In addition, our analyses
showed that the results of AF6 may be presented as a mean
single global score including all six items. The mean single
global score decreased significantly, as did the mean scores
of four of the six items. The importance of SR at 12±3 days
was evident in that the mean scores of five of six items
decreased in responders as compared to no change among
non-responders.
‘Breathing difficulties at rest’ (item 1) was the least
frequent symptom and, when present, had low scores,
indicating very low difficulties among the study population.
In contrast, ‘breathing difficulties upon exertion’ (item 2)
was the second most frequent symptom and showed high
scores, indicating severe difficulties and can thus be
regarded as a symptom of great clinical importance. When
present, ‘worry/anxiety due to atrial fibrillation’ (item 6)
was considered equally as important as ‘tiredness due to
atrial fibrillation’ (item 5) and ‘breathing difficulties upon
exertion’ (item 2). Worry/anxiety due to atrial fibrillation
was most often present and improved among responders,
while it remained unchanged among non-responders. The
role of anxiety and depression has become more apparent in
recent years [16, 17], and the results of the present study
confirm their importance. In one study, higher levels of
reported negative emotions were strongly associated with
the reporting of a greater number of AF symptoms [18].
Table 4 Effect size and standardized response mean between baseline and 12±3 days after DC
AF6 Items All Responders Non-responders
ES SRM ES SRM ES SRM
Breathing difficulties at rest 0.01 0.00 0.11 0.10 −0.13 −0.13
Breathing difficulties upon exertion 0.32 0.33 0.52 0.52 0.09 0.12
Limitations in day-to-day due to atrial fibrillation 0.28 0.25 0.71 0.70 −0.24 −0.21
Feeling of discomfort due to atrial fibrillation 0.29 0.28 0.59 0.64 −0.13 −0.10
Tiredness due to atrial fibrillation 0.53 0.53 0.86 0.83 0.19 0.22
Worry/anxiety due to atrial fibrillation 0.15 0.16 0.28 0.34 −0.04 0.03
Effect sizes were characterized as small (>0.2 but <0.5), moderate (0.5-0.8) or large (>0.8)
J Interv Card Electrophysiol (2010) 28:185–191 189Patients with AF may have a variety of symptoms, from
none to unbearable [19–24]. Patients with few or no
symptoms may not be candidates for DC, but it should be
the patient who determines the level of symptoms. A simple
instrument that can discriminate between patients who
would benefit symptomatically from a DC and those who
would not can therefore play an important role in the
decision as to whether or not to cardiovert. However, it
should also be kept in mind that there are indications for
DC that are independent of symptoms.
While direct current DC has long been an effective
treatment for terminating persistent AF [1, 4, 5], presently
available pharmacological options have not been very
effective in maintaining patients in long-term SR, nor have
they been as safe or tolerable as would be desired.
Immediately after restoration to SR, symptom relief and
improvement of HRQL represent the improvements that
patients expect; but with long-term maintenance of SR,
signs of reverse remodeling can be observed [7–9, 21–26].
In our patients, we found a symptomatic benefit at 12±
3 days after DC. The reason for our follow-up period of 12±
3 days after DC was that little should have happened in the
patient during this period except the change in rhythm. We
allowed the first week for recovery after DC and applied a
7-day recall period.
In the present study, subsequent responders had higher
symptom scores at baseline than subsequent non-
responders, possibly a play of chance, since no selection
was made at baseline. On the other hand there might be
systematic differences between patients who are likely to
maintain SR versus those less likely to maintain SR
following cardioversion. We did not find any important
differences in patient characteristics at baseline, although
the AF episode duration was marginally shorter in
responders. However, the patients who had most symptoms
might have had the shortest AF history and/or least medical
attention up to the time of DC.
In any symptom scale it is important to know the least
change in score that can lead to a clinical improvement.
The effect sizes of the items of the AF6 were calculated
for the whole patient population together and separately
for the subsequent responders and non-responders. The
effect sizes were found to be moderate to low in the whole
study population, consistently low in non-responders and
high in one, moderate in three and low in two of the items
among responders. Since patients with AF are very
heterogeneous with regard to symptoms, effect sizes will
change between treatments and study populations. Never-
theless, the AF6 showed an ability to detect change and
was able to discriminate between more symptomatic and
less symptomatic patients, indicating an ability to also
detect change in populations with a more severe symptom
burden.
6 Limitations
The study was carried out in a population of patients
scheduled for DC who were consecutively enrolled. We do
not know whether the AF6 instrument would have yielded
the same information in other AF populations. Neverthe-
less, AF6 discriminated more symptomatic from less
symptomatic patients. We compared the scores obtained
the day before with those 12±3 days after DC. While this
time may seem short, we wanted to be reasonably sure that
the change in rhythm would be the only thing that occurred
between the measurements.
7 Conclusions
The AF6 showed adequate ability to detect responsiveness
to change and symptom scores measured by the AF6
decreased significantly after DC cardioversion. This was
especially true in clinical responders in maintenance of SR
demonstrating that SR is an important clinical anchor.
Effect sizes were mostly moderate; and in responders,
moderate to high.
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